Format

Send to

Choose Destination
See comment in PubMed Commons below
Gut. 2013 Aug;62(8):1122-30. doi: 10.1136/gutjnl-2011-301769. Epub 2012 Jun 20.

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis.

Author information

1
Department of Medicine, Division of Gastroenterology, University of Leuven, Herestraat 49, 3052 Leuven, Belgium. paul.rutgeerts@uz.kuleuven.ac.be

Abstract

OBJECTIVE:

Etrolizumab (rhuMAb β7, anti-β7, PRO145223) is a humanised monoclonal antibody targeting the β7 subunit of the heterodimeric integrins α4β7 and αEβ7, which are implicated in leucocyte migration and retention in ulcerative colitis (UC). This randomised phase I study evaluated the safety and pharmacology of etrolizumab in patients with moderate to severe UC.

DESIGN:

In the single ascending dose (SAD) stage, etrolizumab (0.3, 1.0, 3.0, 10 mg/kg intravenous, 3.0 mg/kg subcutaneous (SC) or placebo) was administered 4:1 (n=25) in each cohort. In the multiple dose (MD) stage, new patients received monthly etrolizumab (0.5 mg/kg SC (n=4), 1.5 mg/kg SC (n=5), 3.0 mg/kg SC (n=4), 4.0 mg/kg intravenous (n=5)) or placebo (n=5). The pharmacokinetics was studied and Mayo Clinic Score evaluated at baseline, day 29 (SAD), and days 43 and 71 (MD).

RESULTS:

In the SAD stage, there were no dose limiting toxicities, infusion or injection site reactions. Two impaired wound healing serious adverse events occurred in two patients receiving etrolizumab. In the MD stage, there were no dose limiting toxicities, and no infusion or injection site reactions. Headache was the most common adverse event, occurring more often in etrolizumab patients. Antietrolizumab antibodies were detected in two subjects. The duration of β7 receptor full occupancy was dose related. A clinical response was observed in 12/18 patients, and clinical remission in 3/18 patients treated with etrolizumab in the MD stage, compared with 4/5 and 1/5 placebo patients, respectively.

CONCLUSION:

Etrolizumab is well tolerated in moderate to severe UC. Further investigation is warranted.

KEYWORDS:

Crohn's disease; Etrolizumab; IBD; IBD basic research; IBD clinical; IBD models; IBD–genetics; antibody targeted therapy; apoptosis; arthritis; autoimmune disease; cell cycle; cytokines; dendritic cells; drug development; genetics; immunology; inflammatory bowel disorders; integrins; pharmacokinetics; rhuMAb β7; safety; signal transduction; ulcerative colitis

PMID:
22717454
PMCID:
PMC3711369
DOI:
10.1136/gutjnl-2011-301769
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center